Judge Clears Way for Price Lawsuit Against Insulin Manufacturers
Judge denies a motion to dismiss a case against three major drug companies over allegations of price gauging and making it too expensive for diabetics to obtain life-saving insulin.
Drugs & Medical Devices
Maryland Considering Bill to Treat Opioid Addiction with Medical Marijuana
Maryland lawmakers are considering a bill that would list medical marijuana as an effective treatment option for opioid use disorder.
FDA Send a Clear Warning to McKesson Regarding Illegitimate Shipments
The Food and Drug Administration (FDA) sent a warning letter to drug distributor McKesson for incidents in which pharmacies received tampered with shipments of opioids.
Johnson & Johnson Will Include Drug Prices in Television Ads
Johnson & Johnson will improve transparency regarding the cost of certain prescriptions by including pricing in television ads.
Protestors Flood Museums Partially Funded by Sacklers
Protestors flood museums the Sackler family has donated to over the years, asking them to refuse any future funding.
Beware the Potential Consequences of Using an Epidural for Pain
While an epidural seems like a better option for chronic back pain than opioids, there are risks involved, including paraylsis.
Drug Company CEOs Will Testify at Hearing Addressing Price Increases
A hearing will be held at the end of the month in which executives from top drug manufacturers will testify regarding significant price increases.
Illinois Considers Making the Switch from Opioids to Medical Marijuana
Illinois will switch some patients from opioid prescriptions to medical marijuana, which offers a safer alternative.
Doctor Suspected of Causing More Than Two Dozen Patient Deaths
Mount Carmel Hospital System physician, Dr. William Husel, is accused of prescribing high levels of pain medications that led to the deaths of 28 patients.
Government Goes After Insys Executives Using RICO
The federal government uses the Racketeer Influenced and Corrupt Organizations Act (RICO), approved in 1970, to go after Insys executives, claiming they engaged in a racketeering conspiracy scheme to realize revenues from Subsys sales.